Indications and dose
Show For ibuprofen
Pain and inflammation in rheumatic disease and other musculoskeletal disorders, Mild to moderate pain including dysmenorrhoea, Postoperative analgesia, Dental pain for ibuprofen
By mouth using immediate-release medicines
- Adult
- Initially 300–400mg 3–4 times a day; maintenance 200–400mg 3 times a day, increased if necessary up to 600mg 4 times a day.
By mouth using modified-release medicines
- Adult
- 1.6g once daily, dose to be taken in the early evening, increased if necessary to 2.4g daily in 2 divided doses, dose to be increased only in severe cases.
Acute migraine for ibuprofen
By mouth using immediate-release medicines
- Adult
- 400–600mg for 1 dose, to be taken as soon as migraine symptoms develop.
Mild to moderate pain, Pain and inflammation of soft-tissue injuries, Pyrexia with discomfort for ibuprofen
By mouth using immediate-release medicines
- Child 3–5 months
- 50mg 3 times a day, maximum daily dose to be given in 3–4 divided doses; maximum 30mg/kg per day.
- Child 6–11 months
- 50mg 3–4 times a day, maximum daily dose to be given in 3–4 divided doses; maximum 30mg/kg per day.
- Child 1–3 years
- 100mg 3 times a day, maximum daily dose to be given in 3–4 divided doses; maximum 30mg/kg per day.
- Child 4–6 years
- 150mg 3 times a day, maximum daily dose to be given in 3–4 divided doses; maximum 30mg/kg per day.
- Child 7–9 years
- 200mg 3 times a day, maximum daily dose to be given in 3–4 divided doses; maximum 30mg/kg per day; maximum 2.4g per day.
- Child 10–11 years
- 300mg 3 times a day, maximum daily dose to be given in 3–4 divided doses; maximum 30mg/kg per day; maximum 2.4g per day.
- Child 12–17 years
- Initially 300–400mg 3–4 times a day; maintenance 200–400mg 3 times a day, increased if necessary up to 600mg 4 times a day.
Pain and inflammation for ibuprofen
By mouth using modified-release medicines
- Child 12–17 years
- 1.6g once daily, dose preferably taken in the early evening, increased to 2.4g daily in 2 divided doses, dose to be increased only in severe cases.
Pain and inflammation in rheumatic disease including juvenile idiopathic arthritis for ibuprofen
By mouth using immediate-release medicines
- Child 3 months–17 years
- 30–40mg/kg daily in 3 divided doses (max. per dose 800mg), alternatively 30–40mg/kg daily in 4 divided doses (max. per dose 600mg).
Pain and inflammation in systemic juvenile idiopathic arthritis for ibuprofen
By mouth using immediate-release medicines
- Child 3 months–17 years (body-weight up to 40 kg)
- Up to 60mg/kg daily in 4–6 divided doses.
- Child 3 months–17 years (body-weight 40 kg and above)
- Up to 2.4g daily in 4–6 divided doses.
Post-immunisation pyrexia in infants (on doctor’s advice only) for ibuprofen
By mouth using immediate-release medicines
- Child 2–3 months
- 50mg for 1 dose, followed by 50mg for 1 dose, to be given 6 hours after first dose if required.
Pain relief in musculoskeletal conditions, Treatment in knee or hand osteoarthritis (adjunct) for ibuprofen
To the skin
- Adult
- Apply up to 3 times a day, ibuprofen 5% gel to be administered.
Pain and inflammation in rheumatic disease and other musculoskeletal disorders (dose approved for use by community practitioner nurse prescribers), Mild to moderate pain including dysmenorrhoea (dose approved for use by community practitioner nurse prescribers), Migraine (dose approved for use by community practitioner nurse prescribers), Dental pain (dose approved for use by community practitioner nurse prescribers), Headache (dose approved for use by community practitioner nurse prescribers), Fever (dose approved for use by community practitioner nurse prescribers), Symptoms of colds and influenza (dose approved for use by community practitioner nurse prescribers), Neuralgia (dose approved for use by community practitioner nurse prescribers) for ibuprofen
By mouth using immediate-release medicines
- Child 12–17 years
- 200–400mg 3 times a day, if symptoms worsen or persist for more than 3 days refer to doctor.
- Adult
- 200–400mg 3 times a day, if symptoms worsen or persist for more than 10 days refer to doctor.
Mild to moderate pain (dose approved for use by community practitioner nurse prescribers), Pain and inflammation of soft-tissue injuries (dose approved for use by community practitioner nurse prescribers), Pyrexia with discomfort (dose approved for use by community practitioner nurse prescribers) for ibuprofen
By mouth using immediate-release medicines
- Child 3–5 months (body-weight 5 kg and above)
- 20–30mg/kg daily in divided doses, alternatively 50mg 3 times a day for maximum of 24 hours, refer to doctor if symptoms persist for more than 24 hours.
- Child 6–11 months
- 50mg 3–4 times a day, refer to doctor if symptoms persist for more than 3 days.
- Child 1–3 years
- 100mg 3 times a day, refer to doctor if symptoms persist for more than 3 days.
- Child 4–6 years
- 150mg 3 times a day, refer to doctor if symptoms persist for more than 3 days.
- Child 7–9 years
- 200mg 3 times a day, refer to doctor if symptoms persist for more than 3 days.
- Child 10–11 years
- 300mg 3 times a day, refer to doctor if symptoms persist for more than 3 days.
Post-immunisation pyrexia in infants (dose approved for use by community practitioner nurse prescribers) (on doctor’s advice only) for ibuprofen
By mouth using immediate-release medicines
- Child 3 months
- 50mg for 1 dose, followed by 50mg for 1 dose, to be given 6 hours after first dose if required, if pyrexia persists refer to doctor.
Acute moderate pain, Pyrexia for ibuprofen
By intravenous infusion
- Child 6–17 years (body-weight 20–29 kg)
- 200mg 3 times a day as required for maximum 3 days, doses to be given at intervals of at least 6 hours; maximum 600mg per day.
- Child 6–17 years (body-weight 30–39 kg)
- 200mg 4 times a day as required for maximum 3 days, doses to be given at intervals of at least 6 hours; maximum 800mg per day.
- Child 6–17 years (body-weight 40 kg and above)
- 200–400mg 3 times a day as required for maximum 3 days, doses to be given at intervals of at least 6 hours; maximum 1.2g per day.
Acute moderate pain for ibuprofen
By intravenous infusion
- Adult
- 400mg 3 times a day as required for maximum 3 days, doses to be given at intervals of at least 6 hours, alternatively 600mg twice daily as required for maximum 3 days, doses to be given at intervals of at least 6 hours; maximum 1.2g per day.
Pyrexia for ibuprofen
By intravenous infusion
- Adult
- 400mg 3 times a day as required for maximum 3 days, doses to be given at intervals of at least 6 hours; maximum 1.2g per day.
Show For Fenbid® Forte
Pain relief in musculoskeletal conditions, Treatment in knee or hand osteoarthritis (adjunct) for Fenbid® Forte
To the skin
- Adult
- Apply up to 4 times a day, therapy should be reviewed after 14 days.
Show For Ibugel® Forte
Pain relief in musculoskeletal conditions, Treatment in knee or hand osteoarthritis (adjunct) for Ibugel® Forte
To the skin
- Adult
- Apply up to 3 times a day.
Unlicensed use
Unlicensed use For ibuprofen
With oral use in children:
Not licensed for use in children aged under 3 months or with body-weight under 5kg.
Maximum dose for systemic juvenile idiopathic arthritis is unlicensed.
Important safety information
Important safety information For ibuprofen
MHRA/CHM advice: NSAIDs: potential risks following prolonged use after 20 weeks of pregnancy (June 2023)
With systemic use:
See Non-steroidal anti-inflammatory drugs.
Contra-indications
Contra-indications For ibuprofen
With intravenous use
Active bleeding (especially intracranial or gastro-intestinal); thrombocytopenia
With systemic use
Active gastro-intestinal bleeding; active gastro-intestinal ulceration; history of gastro-intestinal bleeding related to previous NSAID therapy; history of gastro-intestinal perforation related to previous NSAID therapy; history of recurrent gastro-intestinal haemorrhage (two or more distinct episodes); history of recurrent gastro-intestinal ulceration (two or more distinct episodes); severe heart failure; varicella infection
Cautions
Cautions For ibuprofen
With systemic use
Allergic disorders; cardiac impairment (NSAIDs may impair renal function); cerebrovascular disease; coagulation defects; connective-tissue disorders; dehydration (risk of renal impairment); elderly (risk of serious side-effects and fatalities) (in adults); heart failure; history of gastro-intestinal disorders (e.g. ulcerative colitis, Crohn’s disease); ischaemic heart disease; may mask symptoms of infection; peripheral arterial disease; risk factors for cardiovascular events; uncontrolled hypertension
With topical use
Avoid contact with eyes (in adults); avoid contact with inflamed or broken skin (in adults); avoid contact with mucous membranes (in adults); not for use with occlusive dressings (in adults); topical application of large amounts can result in systemic effects, including hypersensitivity and asthma (renal disease has also been reported) (in adults)
Cautions, further information
High-dose ibuprofen
With oral use:
A small increase in cardiovascular risk, similar to the risk associated with cyclo-oxygenase-2 inhibitors and diclofenac, has been reported with high-dose ibuprofen (≥ 2.4g daily); use should be avoided in patients with established ischaemic heart disease, peripheral arterial disease, cerebrovascular disease, congestive heart failure (New York Heart Association classification II-III), and uncontrolled hypertension.
Masking of symptoms of underlying infections
With systemic use:
Ibuprofen can mask symptoms of infection, which may lead to delayed initiation of appropriate treatment and thereby worsen infection outcome. This has been observed in bacterial community-acquired pneumonia and bacterial complications to varicella. When administered for fever or pain relief in relation to infection, monitoring of infection is advised.
Interactions
View interactions for ibuprofen
Side-effects
Side-effects For ibuprofen
General side-effects:
Common or very common
Gastrointestinal discomfort; skin reactions
Uncommon
Asthma; hypersensitivity
Rare or very rare
Dyspnoea
Specific side-effects:
Common or very common
With intravenous use
Constipation; diarrhoea; dizziness; fatigue; gastrointestinal disorders; haemorrhage; headache; inflammatory bowel disease; insomnia; nausea; oral disorders; vertigo; vomiting
Uncommon
With intravenous use
Acute kidney injury; anxiety; irritability; nephritis tubulointerstitial; nephrotic syndrome; oedema; tinnitus; vasculitis; vision disorders
With oral use
Headache; nausea; rash (discontinue)
Rare or very rare
With intravenous use
Agranulocytosis; alopecia; anaemia; auditory disorder; confusion; depression; heart failure; hepatic disorders; hypertension; hypotension; infection exacerbated; leucopenia; meningitis aseptic (patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible); myocardial infarction; neck stiffness; palpitations; pancreatitis; pancytopenia; photosensitivity reaction; psychotic disorder; renal papillary necrosis; respiratory disorders; severe cutaneous adverse reactions (SCARs); shock; systemic lupus erythematosus (SLE); thrombocytopenia
With oral use
Acute kidney injury; agranulocytosis; anaemia; angioedema; constipation; diarrhoea; gastrointestinal disorders; haemorrhage; leucopenia; liver disorder; meningitis aseptic (patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible); oedema; oral ulceration; pancytopenia; renal papillary necrosis; severe cutaneous adverse reactions (SCARs); shock; thrombocytopenia; vomiting
Frequency not known
With intravenous use
Increased risk of arterial thromboembolism
With oral use
Crohn's disease; fertility decreased female; fluid retention; heart failure; hypertension; increased risk of arterial thromboembolism; renal failure (more common in patients with pre-existing renal impairment); respiratory disorders; respiratory tract reaction
With topical use
Angioedema (in adults); bronchospasm (in adults); rash (discontinue) (in adults); renal impairment (in adults); toxic epidermal necrolysis (in adults)
Side-effects, further information
For information about cardiovascular and gastrointestinal side-effects, and a possible exacerbation of symptoms in asthma, see Non-steroidal anti-inflammatory drugs
With topical use
Topical application of large amounts can result in systemic effects, including hypersensitivity and asthma (renal disease has also been reported).
Overdose
Overdosage with ibuprofen may cause nausea, vomiting, epigastric pain, and tinnitus, but more serious toxicity is very uncommon. Charcoal, activated followed by symptomatic measures are indicated if more than 100 mg/kg has been ingested within the preceding hour.
For details on the management of poisoning, see Emergency treatment of poisoning.
Allergy and cross-sensitivity
Allergy and cross-sensitivity For ibuprofen
Contraindicated in patients with a history of hypersensitivity to aspirin or any other NSAID—which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID. M
Conception and contraception
Conception and contraception For ibuprofen
With systemic use:
Caution—long-term use of some NSAIDs is associated with reduced female fertility, which is reversible on stopping treatment. M
Pregnancy
Pregnancy For ibuprofen
With systemic use:
Avoid use in first and second trimesters unless essential; the MHRA advises additional antenatal monitoring may be required if treatment is considered necessary by a doctor from week 20 of pregnancy onwards.
Avoid use in third trimester.
See NSAIDs in Pregnancy in Non-steroidal anti-inflammatory drugs for further details.
With topical use in adults:
Patient packs for topical preparations carry a warning to avoid during pregnancy.
Breast feeding
Breast feeding For ibuprofen
Specialist sources indicate suitable for use in breast-feeding—negligible amounts present in milk.
Hepatic impairment
Hepatic impairment For ibuprofen
With systemic use for indications relating to Pain or Pyrexia:
Caution in mild to moderate impairment; avoid in severe impairment. M
Dose adjustments
With systemic use for indications relating to Pain or Pyrexia:
The lowest effective dose should be used for the shortest possible duration. M
Renal impairment
Renal impairment For ibuprofen
With systemic use for indications relating to Pain or Pyrexia:
In general, for NSAIDs the MHRA advises to avoid where possible; if necessary, use with caution (risk of fluid retention and further renal impairment, including renal failure).
For ibuprofen, avoid in severe impairment. M
With topical use in adults:
Caution (deterioration in renal function has also been reported after topical use). M
Dose adjustments
With systemic use for indications relating to Pain or Pyrexia:
The lowest effective dose should be used for the shortest possible duration. M
Directions for administration
Directions for administration For ibuprofen
With intravenous use:
For intravenous infusion, give over 30 minutes.
With topical use in adults:
For topical preparations, apply with gentle massage only.
Prescribing and dispensing information
Prescribing and dispensing information For ibuprofen
With oral use:
Flavours of syrup may include orange.
With topical use in children:
Caution—topical preparations not generally suitable for children.
Patient and carer advice
Patient and carer advice For ibuprofen
With topical use in adults:
For topical preparations, patients and their carers should be advised to wash hands immediately after use.
Photosensitivity
With topical use in adults:
For topical preparations, patients or their carers should be advised against excessive exposure to sunlight of area treated in order to avoid possibility of photosensitivity.
Medicines for Children leaflet: Ibuprofen for pain and inflammation
In children:
https://www.medicinesforchildren.org.uk/medicines/ibuprofen-for-pain-and-inflammation/
Profession specific information
Profession specific information For ibuprofen
Dental practitioners' formulary
With oral use:
Ibuprofen Oral Suspension Sugar-free may be prescribed.
Ibuprofen Tablets may be prescribed.
Exceptions to legal category
Exceptions to legal category For ibuprofen
With topical use in adults:
Smaller pack sizes of gel preparations may be available on sale to the public.
With oral use:
Oral preparations can be sold to the public in certain circ*mstances.
Medicinal forms
There can be variation in the licensing of different medicines containing the same drug.
Forms available from special-order manufacturers include: oral suspension.
View all medicinal forms and pricinginformation
Or jump straight to:
- Oral tablet
- Orodispersible tablet
- Modified-release tablet
- Oral capsule
- Chewable capsule
- Modified-release capsule
- Effervescent granules
- Oral suspension
- Solution for infusion
- Cutaneous gel
- Anal fissure
- Analgesics
- Ear
- Herpesvirus infections
- Migraine
- Non-steroidal anti-inflammatory drugs
- Peri-operative analgesia
- Sinusitis (acute)
- Soft-tissue disorders
Related Nurse Prescribers’ treatment summaries
- Analgesics
Other drugs in class
Other drugs in classNon-steroidal anti-inflammatory drugs
- Aceclofenac
- Aspirin
- Aspirin with codeine
- Aspirin with metoclopramide
- Benzydamine hydrochloride
- Bromfenac
- Celecoxib
- Dexketoprofen
- Diclofenac
- Diclofenac potassium
- Diclofenac sodium
- Diclofenac sodium with misoprostol
- Etodolac
- Etoricoxib
- Felbinac
- Flurbiprofen
- Indometacin
- Ketoprofen
- Ketorolac trometamol
- Mefenamic acid
- Meloxicam
- Nabumetone
- Naproxen
- Naproxen with esomeprazole
- Nepafenac
- Parecoxib
- Phenazone with lidocaine
- Piroxicam
- Sulindac
- Tenoxicam
- Tiaprofenic acid
- Tolfenamic acid
- Tramadol with dexketoprofen